Association between RAD51 gene polymorphism (-135G/C) and susceptibility of myelodysplastic syndrome and acute leukemia: evidence based on a meta-analysis

Tumour Biol. 2014 Jan;35(1):615-21. doi: 10.1007/s13277-013-1085-4. Epub 2013 Aug 17.

Abstract

Study results on the association between RAD51 gene -135G/C polymorphism and risk of myelodysplastic syndrome (MDS) or acute leukemia are inconsistent. A meta-analysis was conducted to identify the association. A systematic search was performed in PubMed, Embase, CNKI, VIP, Wanfang databases to collect all relevant studies until January 2013. Meta-analysis was carried out using fixed/random model by Review Manager 5.1 and STATA10.0. A total of 10 eligible studies with 2,656 patients and 3,725 controls were included in meta-analysis. Significant association was detected between -135G/C polymorphism and increased MDS risk (CC + GC vs. GG: OR = 1.46, 95% CI = 1.11-1.92; CC vs. GC + GG: OR = 2.45, 95% CI = 1.23-4.89), while no association was observed for acute leukemia. Subgroup analysis by subtypes of acute leukemia and ethnicity showed no significant results either. Our meta-analysis indicated that the -135G/C polymorphism might be associated with increased susceptibility of MDS. However, lack of evidence supported association of this polymorphism with acute leukemia. Additional well-designed studies with larger samples are required to verify our results.

Publication types

  • Meta-Analysis

MeSH terms

  • Alleles
  • Case-Control Studies
  • Genetic Association Studies
  • Genetic Predisposition to Disease*
  • Genotype
  • Humans
  • Leukemia, Myeloid, Acute / ethnology
  • Leukemia, Myeloid, Acute / genetics*
  • Myelodysplastic Syndromes / ethnology
  • Myelodysplastic Syndromes / genetics*
  • Odds Ratio
  • Polymorphism, Single Nucleotide*
  • Publication Bias
  • Rad51 Recombinase / genetics*

Substances

  • Rad51 Recombinase